CLINICAL_TRIALS ClinicalTrials.gov record update

CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02529813
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:36.212523+00:00
Published At: 2022-06-30T00:00:00+00:00
Record Updated At: 2022-06-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "CD19 Positive", "Minimal Residual Disease", "Non-Hodgkin Lymphoma", "Small Lymphocytic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-06-30"
protocolSection.identificationModule.nctId: "NCT02529813"
protocolSection.identificationModule.officialTitle: "CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.